Can RNA Therapy Redefine Hypertension Treatment?

Why does hypertension remain uncontrolled despite cheap, effective drugs?

Hypertension is one of medicine's most established treatment markets. Yet control remains uneven despite a large, inexpensive armamentarium of ACE inhibitors, ARBs, calcium-channel blockers, diuretics, beta blockers and fixed-dose combinations^[1]. The challenge is not a lack of pharmacology. It is the gap between a treatment prescribed and treatment taken consistently over years.

Daily oral antihypertensive therapy works when it is taken consistently and appropriately combined. In practice, hypertension management is often complicated by polypharmacy, treatment fatigue, adverse effects, cost, variable follow-up and the fact that high blood pressure is frequently asymptomatic^[2].

That creates an enduring commercial paradox: effective therapies are widely available, but sustained blood-pressure control remains difficult to achieve at population scale. For Alnylam, Roche, Ionis Pharmaceuticals, Kardigan Bio, SanegeneBio, Innovent and other RNA-focused biotechs, the opportunity is to change the treatment model, not merely introduce another antihypertensive medicine.

What defines the RNA-hypertension value proposition?

Seven terms, taken together, define whether a long-acting RNA medicine earns a place in hypertension care. Select a term to see what is at stake.

The next hypertension breakthrough may not be a more potent daily pill. It may be a treatment model that turns adherence from an individual, daily patient responsibility into a scheduled, health-system-supported care event.

Why has angiotensinogen become the strategic target?

Angiotensinogen sits upstream in the renin-angiotensin-aldosterone system. Rather than blocking a downstream receptor or enzyme with a daily pill, RNA-based medicines aim to reduce the production of angiotensinogen itself^[3]. The modality changes the commercial proposition.

1. 01

   Administration moves from daily to infrequent

   Daily oral dosing gives way to infrequent subcutaneous administration under investigation.

2. 02

   Treatment responsibility becomes shared

   Responsibility shifts from primarily the patient and pharmacy-refill system to being shared across patient, clinic, provider and scheduling infrastructure.

3. 03

   The evidence bar rises

   Established therapy carries proven efficacy, generics and long-term familiarity. An RNA approach must demonstrate durable control, manageable safety, outcomes value and practical implementation.

The distinction matters. A long-acting intervention does not remove the need for clinical follow-up, nor does it replace established oral therapy immediately. What it could do is make durable blood-pressure lowering less dependent on daily adherence.

What is zilebesiran and why does ZENITH matter?

Zilebesiran, developed by Alnylam and partnered with Roche, is the most advanced high-profile example of this new treatment model. It is an investigational siRNA therapy designed to reduce hepatic production of angiotensinogen and support sustained blood-pressure lowering with infrequent administration. In 2025, Alnylam and Roche advanced zilebesiran into the global Phase III ZENITH cardiovascular-outcomes trial^[3].

The ZENITH study is designed to enroll approximately 11,000 people with uncontrolled hypertension who are receiving background antihypertensive therapy and have established cardiovascular disease or elevated cardiovascular risk^[3]. Its strategic importance goes beyond a blood-pressure endpoint. It asks whether long-acting RNA therapy can generate the kind of cardiovascular-outcomes evidence required to earn a role in a low-cost, generic-dominated treatment market.

Roche reported that its KARDIA-3 program showed clinically meaningful placebo-adjusted reductions in office systolic blood pressure at three months with control sustained through six months. The development story also illustrates the evidence challenge: KARDIA-3 did not meet its predefined statistical significance for one of its specified office systolic-blood-pressure comparisons, even as the companies moved the program into Phase III^[4].

For Alnylam and Roche, the opportunity is therefore larger than launching a differentiated antihypertensive. A positive outcomes program could validate RNA interference in a prevalent chronic disease, creating a strategic bridge from rare and specialty indications to population-scale cardiometabolic medicine.

Who else is targeting angiotensinogen with RNA medicines?

Zilebesiran may be the leading commercial proof point, but it is not the only attempt to use nucleic-acid medicines to influence angiotensinogen. Ionis Pharmaceuticals has licensed tonlamarsen, an investigational antisense oligonucleotide targeting angiotensinogen, to Kardigan Bio. SanegeneBio and Innovent are developing SGB-3908/IBI3016, a GalNAc-conjugated siRNA approach directed at the same target.

Early reporting from the KARDINAL study showed substantial reductions in plasma angiotensinogen with tonlamarsen, while the strength and consistency of blood-pressure effects remain a central question for the program^[5]. The presence of SGB-3908/IBI3016 reinforces that hypertension could become an international platform race across RNA chemistry, delivery, dose interval, safety and clinical execution^[6].

The emerging competition is therefore not simply RNA versus pills. It is a contest over which platform can offer the most credible combination of sustained control, manageable risk, patient convenience, provider workflow fit and economic value.

What changes when a prescription becomes a scheduled care event?

If approved, long-acting RNA therapy could change how hypertension is delivered. A daily generic antihypertensive can be prescribed by primary care and dispensed at scale through retail pharmacies. An infrequently administered RNA medicine may require a more structured model: benefit verification, appointment scheduling, administration capacity, follow-up protocols and persistence tracking.

That creates a new account map. Primary-care practices identify appropriate uncontrolled-hypertension populations, coordinate background therapy and manage longitudinal care. Cardiologists and hypertension specialists shape early adoption, patient selection and treatment protocols for higher-risk patients. Health systems and integrated delivery networks build administration, scheduling and population-health pathways around infrequent therapy, while hospital outpatient departments and ambulatory clinics may serve as early sites of administration, particularly for complex or high-risk patients.

Pharmacies and specialty-pharmacy partners support benefit investigation, patient follow-up and coordination, even when therapy is administered in clinic. Payers and pharmacy-benefit organizations determine utilization-management and reimbursement in a market dominated by low-cost oral generics. Employers and population-health organizations may evaluate whether reliable blood-pressure control can reduce downstream cardiovascular risk and avoidable care use.

The key question is whether the care model can scale beyond cardiology and specialist hypertension clinics. If it cannot, RNA therapy may remain a high-risk niche product. If it can be integrated into primary-care and population-health workflows, it could create a much larger market.

What are the leading companies signaling in RNA hypertension?

The message is not that RNA medicines will replace all oral antihypertensives. Instead, they may create a distinct treatment category for selected patients where uncontrolled blood pressure, cardiovascular risk and adherence limitations justify a more structured intervention.

In the US, the commercial challenge will be demonstrating that a high-cost RNA medicine is justified for defined patients who remain uncontrolled despite standard therapy. In Europe, companies may face more centralized evaluation of comparative value, affordability and system capacity^[7].

What must an emerging RNA-hypertension program answer?

For biotech companies, hypertension is both an opportunity and a warning. The addressable population is enormous, but so is the evidence and commercial bar. The strategic question is which patients benefit sufficiently beyond standard oral combinations to justify a new care model.

For smaller platform companies, the opportunity may not be to outspend Roche or Alnylam on a single large outcomes trial. It may be to differentiate through delivery chemistry, target selection, dosing profile, combination strategy or partnerships that connect RNA innovation to primary-care-scale infrastructure.

What is still unresolved in the hypertension market?

The future of hypertension therapy may not hinge on whether another medicine can lower blood pressure. Many medicines already can. The more important question is whether companies can build a treatment model that produces reliable control across months and years, in the patients who remain at highest cardiovascular risk despite available oral therapy.

Those questions sit with the people shaping hypertension care: primary-care physicians, cardiologists and hypertension specialists, health-system and population-health leaders, pharmacy and specialty-pharmacy partners, payers and pharmacy-benefit organizations, and former industry executives.

The next hypertension winner may not be the therapy with the lowest blood-pressure reading at a single visit. It may be the therapy that best turns durable blood-pressure control into a practical, affordable and repeatable model of care.